Daihan Pharmaceutical Co., Ltd. (023910) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daihan Pharmaceutical Co., Ltd. (023910:KRX), powered by AI.

Current Price
₩26,600
P/E Ratio
5.8
Market Cap
159.6B
Sector
Healthcare
What is the Daihan Pharmaceutical Co., Ltd. stock price forecast?

Daihan Pharmaceutical Co., Ltd. is currently trading at ₩26,600. View real-time AI analysis on Alpha Lenz.

What is Daihan Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Daihan Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Daihan Pharmaceutical Co., Ltd.'s P/E ratio?

Daihan Pharmaceutical Co., Ltd.'s P/E ratio is 5.8.

Daihan Pharmaceutical Co., Ltd.

KRX · 023910
₩26,600-100(-0.37%)Market closedKRX regular session 09:00–15:30 KST
Ask about Daihan Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Daihan Pharmaceutical Co., Ltd. trades at a P/E of 5.8 (undervalued) with solid ROE of 9.6%.

Ask for details

Company Overview

Daihan Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry focused on the development, manufacturing, and marketing of an extensive range of medicinal products. The company specializes in producing over-the-counter drugs, prescription medicines, and health supplements, playing a crucial role in addressing various health conditions and improving patient outcomes. Daihan Pharmaceutical is known for its innovative approach to research and development, ensuring a steady pipeline of new and effective treatments. The company serves a widespread market, contributing significantly to the healthcare sector's advancement by catering to hospitals, clinics, and pharmacies. With its headquarters located in South Korea, Daihan Pharmaceutical has established itself as a vital entity in the Asian pharmaceutical landscape. Its strategic partnerships and rigorous adherence to quality control enhance its market significance, ensuring the delivery of high-standard products that meet global health safety guidelines.

CEO이승영
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩159,600,000,000Market Cap
₩208,614,118,260Revenue
6.00MShares Out
0Employees

Margins

31.07%Gross
20.17%EBITDA
14.95%Operating
15.89%Pre-Tax
13.25%Net

Valuation

5.77P/E
0.53P/B
0.77EV/Sales
2.75EV/EBITDA
331.44P/FCF

Growth (CAGR)

4.22%Rev 3Yr
4.67%Rev 5Yr
-1.84%Op Inc 3Yr
0.80%Op Inc 5Yr
3.46%Net Inc 3Yr
9.72%Net Inc 5Yr

Returns

8.23%ROA
9.60%ROE
9.87%ROIC

Financial Health

₩43,972,786,130Cash & Cash Equivalents
₩3,476,964,350Net Debt
15.81%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Daihan Pharmaceutical Co., Ltd. (ticker: 023910) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $159.6B.

The current price is ₩26,600 with a P/E ratio of 5.77x and P/B of 0.53x.

ROE is 9.60% and operating margin is 14.95%. Annual revenue is $208.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Daihan Pharmaceutical Co., Ltd. (023910) Stock Forecast 2026 ₩26,600 — Price, Financials & Analyst Targets | Alpha Lenz